Pre-made Itepekimab benchmark antibody ( Whole mAb, anti-IL33 therapeutic antibody, Anti-C9orf26/DVS27/IL1F11/NF-HEV/NFEHEV Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-283

Pre-Made Itepekimab biosimilar, Whole mAb, Anti-IL33 Antibody: Anti-C9orf26/DVS27/IL1F11/NF-HEV/NFEHEV therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Itepekimab is an anti-interleukin-33 (IL-33) monoclonal antibody being developed by Sanofi, in collaboration with Regeneron Pharmaceuticals, for the treatment.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-283-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Itepekimab biosimilar, Whole mAb, Anti-IL33 Antibody: Anti-C9orf26/DVS27/IL1F11/NF-HEV/NFEHEV therapeutic antibody
INN Name Itepekimab
TargetIL33
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesRegeneron Pharmaceuticals;Sanofi
Conditions Approvedna
Conditions ActiveChronic obstructive pulmonary disease
Conditions DiscontinuedAllergic asthma;Inflammation;Asthma;Atopic dermatitis
Development Techna